FAM107A抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P08308(FAM107A Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P08308(FAM107A Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The FAM107A (Family with sequence similarity 107 member A) protein, also known as DRR1 (downregulated in renal cell carcinoma 1) or TUBA, is encoded by the FAM107A gene located on chromosome 3p21.1. Initially identified as a tumor suppressor, FAM107A is frequently downregulated in various cancers, including gliomas, lung, gastric, and prostate cancers, often due to promoter hypermethylation or chromosomal deletions. It plays roles in cell migration, proliferation, apoptosis, and epigenetic regulation, interacting with histone deacetylases (HDACs) and microtubules to influence cytoskeletal dynamics. FAM107A is also implicated in neurodevelopment and neuronal differentiation, with altered expression linked to neurodevelopmental disorders.

Antibodies targeting FAM107A are critical tools for studying its expression, localization, and function. These antibodies, typically polyclonal or monoclonal (produced in rabbits or mice), are validated for applications like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. They help detect FAM107A in tissue/cell lysates, assess its downregulation in tumors, and explore its interaction partners. Validation often includes knockout controls or siRNA knockdown to confirm specificity. Clinically, FAM107A antibodies aid in evaluating its potential as a prognostic biomarker or therapeutic target. Research-grade antibodies are commercially available, but optimization for specific assays (e.g., fixation methods) is recommended to ensure accuracy.